Program
HSK7653
A development code. Also written as “HSK7653 10 mg”, “HSK7653 10 mg Q2W” and “HSK7653 25 mg Q2W”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Glucose Intolerance · Renal Insufficiency, led by Haisco Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haisco Pharmaceutical Group | 100 open or running | phase 3since Sep 14, 2020 | Aug 25, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 25, 2020First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT04540016 · 6 enrolled · China
- Sep 14, 20202 phase 3 studies in Diabetes Mellitus, Type 2NCT04564872, NCT04556851
- Jan 21, 2021Phase 2 study in Glucose IntoleranceNCT04727580 · 99 enrolled · China
- Aug 9, 2022Phase 1 study in Renal InsufficiencyNCT05497297 · 42 enrolled · China
- Jan 11, 2023Phase 1 study in HealthyNCT06003088 · 48 enrolled · China
- Aug 1, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05983289 · 62 enrolled · China
- Sep 23, 2023Phase 2 study in Diabetes Mellitus, Type 2NCT06059326 · 48 enrolled · China
- Sep 24, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT06084156 · 22 enrolled · China
- Nov 21, 2024Phase 2 study in Diabetes Mellitus, Type 2NCT06703268 · 64 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06703268Diabetes Mellitus, Type 2 · China | 2 | Completed | Oct 5, 2024 | 64 |
| NCT06084156Diabetes Mellitus, Type 2 · China | 1 | Completed | Dec 9, 2019 | 22 |
| NCT06059326Diabetes Mellitus, Type 2 · China | 2 | Completed | Nov 5, 2019 | 48 |
| NCT05983289Diabetes Mellitus, Type 2 · China | 1 | Completed | Jul 3, 2019 | 62 |
| NCT06003088Healthy · China | 1 | Completed | Aug 12, 2022 | 48 |
| NCT05497297Renal Insufficiency · China | 1 | Completed | Oct 23, 2022 | 42 |
| NCT04727580Glucose Intolerance · China | 2 | Completed | Jun 12, 2022 | 99 |
| NCT04564872Diabetes Mellitus, Type 2 · China | 3 | Completed | Jan 21, 2022 | 465 |
| NCT04556851Diabetes Mellitus, Type 2 · China | 3 | Completed | Jan 10, 2022 | 476 |
| NCT04540016Diabetes Mellitus, Type 2 · China | 1 | Completed | Jan 14, 2021 | 6 |
How it is read
Names in the registry
- “HSK7653 10 mg”, 2 entries
- “HSK7653”, 2 entries
- “HSK7653 10 mg Q2W”, 2 entries
- “HSK7653 25 mg Q2W”, 2 entries
- “HSK7653 10mg Q2W”, 1 entry
Codes read as this program: HSK7653.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 7 studies
- Glucose Intolerance, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.